• No results found

Clinical pharmacology of ertapenem in the treatment of multidrug-resistant tuberculosis

N/A
N/A
Protected

Academic year: 2021

Share "Clinical pharmacology of ertapenem in the treatment of multidrug-resistant tuberculosis"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Clinical pharmacology of ertapenem in the treatment of multidrug-resistant tuberculosis van Rijn, Sander Pascal

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

van Rijn, S. P. (2019). Clinical pharmacology of ertapenem in the treatment of multidrug-resistant tuberculosis. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

Behorende bij het proefschrift

Clinical pharmacology of ertapenem in the

treatment of Multidrug-resistant Tuberculosis

1. 2. 3. 4. 5. 6. 7. 8. 9.

Ertapenem, in combinatie met een betalactamase-remmer zoals clavulanaat, is een waardevolle aanwinst in de behandeling van multidrug-resistente tuberculose en dient te worden opgenomen in groep C in de WHO-richtlijn – dit proefschrift

Carbapenems, waaronder ertapenem, zijn een goed alternatief voor amikacin in de behandeling van multidrug-resistente tuberculosis – dit proefschrift

De herbestemming van geneesmiddelen is een betaalbare en toegankelijke manier om nieuwe behandelingen voor (zeldzame) ziekten te ontwikkelen – dit proefschrift

Het Hollow-fiber model kan traditionele dierexperimenten vervangen bij het evalueren van PK/PD-parameters – dit proefschrift

Genotypische testen hebben de toekomst bij het monitoren van resistentie – dit proefschrift

Tuberculose kan alleen voorkomen en genezen worden als het wereldwijde jaarlijkse financieringstekort van 1,3 miljard euro wordt aangevuld door rijke westerse landen – dit proefschrift

“Wetenschap is de titanische poging van het menselijk intellect zich uit zijn kosmische isolement te verlossen door te begrijpen” – Willem Frederik Hermans, Nooit meer slapen

“Leef, reis, ga op avontuur, wees dankbaar en heb nergens spijt van.” - Jack Kerouac

Referenties

GERELATEERDE DOCUMENTEN

Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Management of patients

Ultimately, 37 articles were included describing in vitro susceptibility testing of levofloxacin against MDR-TB strains, and clinical studies on pharmacokinetic monitoring

Al- though 86 % of patients with drug susceptible TB are cured with estab- lished first line drugs, treatment is often longer than six months due to slow response, compliance

Treatment success rate is a potentially biased outcome parameter; our primary efficacy end point to estimate the usefulness of LFX was time to sputum culture conversion within

The last study [33] developed and validated a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method for the analysis of

Therefore, membrane filtration was found to be suitable for sterilization of saliva samples, before analyzing for therapeutic drug monitoring purposes (7). However, it is likely that

In this prospective pharmacokinetic study (May 2016 to October 2017; ERB approval no. 115/2016), we aimed to evaluate the factors associated with time to sputum culture conversion

Saliva may be a useful alternative matrix for monitoring levofloxacin concentrations in multi-drug resistant TB patients. The objectives of this study were: a) to evaluate